Evidence map›Paper›PMID 40754873›Full record

ReviewCurrent topics in medicinal chemistry2026

INHBA: A Protein-coding Gene Closely Related to Tumour Diseases.

Jiayi Ma, Yining Pan, Cheng Chen, Dongshuo Wang, Xiaolan Li, Chengfu Yuan

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current topics in medicinal chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Jiayi MaHubei Key Laboratory of Tumor Microenvironment and Immunotherapy, China Three Gorges University, Yichang, China.
Yining PanHubei Key Laboratory of Tumor Microenvironment and Immunotherapy, China Three Gorges University, Yichang, China.
Cheng ChenHubei Key Laboratory of Tumor Microenvironment and Immunotherapy, China Three Gorges University, Yichang, China.
Dongshuo WangHubei Key Laboratory of Tumor Microenvironment and Immunotherapy, China Three Gorges University, Yichang, China.
Xiaolan LiThe Second People's Hospital of China Three Gorges University, Yichang, China.
Chengfu YuanHubei Key Laboratory of Tumor Microenvironment and Immunotherapy, China Three Gorges University, Yichang, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionAt present, malignant tumors are still under development with an increasing trend, and their prevention, treatment, and prognosis are also difficult. The INHBA gene, also known as inhibin β, has a wide range of roles to play in this context. Through studies, several researchers have confirmed that an abnormal expression of the INHBA gene affects the development and prognosis of several malignant tumors (cervical, colorectal, breast, gastric, etc.). This study aims to investigate the relationship between INHBA and the occurrence, development, treatment, and prognosis of malignant tumors.

methodsThis review, which involved scanning of pertinent literature, describes and evaluates recent research on the biological functions and mechanisms of INHBA in malignancies.

resultsAn aberrant expression of INHBA can lead to a variety of tumors, including cervical, esophageal, breast, colorectal, squamous cell, bladder, nasopharyngeal, gastric, and ovarian cancers. DISCUSSION: INHBA, as a protein-coding gene, can affect the development of various tumors and the prognosis of tumor patients, suggesting that INHBA can be a target for tumor therapy. However, the research on targeted therapy is still immature and has certain safety risks.

conclusionResearch findings indicate that the INHBA gene plays a role in both carcinogenesis and prognosis. As such, it may have the potential utility as a biomarker or therapeutic target in the treatment of malignant tumors.

Indexed as

Inhibin-beta SubunitsNeoplasmsHumansPrognosisInhibin-beta SubunitsBreast cancerCervical cancerColorectal cancerGastric cancerINHBAOncologyPreventive therapy

Identifiers

PMID40754873

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.